Terns Pharmaceuticals Inc
(STU:430)
€
5.6
0.05 (0.9%)
Market Cap: 470.26 Mil
Enterprise Value: 113.82 Mil
PE Ratio: 0
PB Ratio: 1.34
GF Score: 39/100 Terns Pharmaceuticals Inc at H.C. Wainwright & Co LLC 7th Annual NASH Investor Conference (Virtual) Transcript
Oct 24, 2023 / 06:30PM GMT
Release Date Price:
€5.06
(-2.32%)
Ed Arce
H.C. Wainwright & Co. - Analyst
Hello, and welcome to the H.C. Wainwright 7th Annual NASH Investor Conference. My name is Ed Arce, I'm one of the senior analysts here at HCW. And I'm pleased to have with us now our next presenting company Terns Pharmaceuticals and representing the company is Justin Ng. He is the Director of Corporate Development and Investor Relations. Justin, so glad you could join us today.
Justin Ng
Terns Pharmaceuticals, Inc. - Director, Corporate Development & IR
Thanks, Ed. Nice to see you, and thanks to you and the H.C. Wainwright team for the invite today.
Questions & Answers
Ed Arce;Justin Ng
H.C. Wainwright & Co. - Analyst;Terns Pharmaceuticals, Inc. - Director,
Absolutely. So let's dive in. I know your pipeline lends itself to several different areas of interest. So perhaps for those investors who may not be as well aware, we could just start with an overview of the company, your strategy, and your pipeline candidates.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot